On Air Now

Now Playing

KATY PERRY

TEENAGE DREAM

Download

World's First Covid-19 Treatment Trial With Sepsis Underway in London

stock photo

Scientists at The Lawson Health Research Institute in London are optimistic about the treatment using the Annexin A5 protein, which has been used successfully with patients who have sepsis.

LONDON - A new trial involving 60 patients will be the first in the world to receive treatment for COVID-19 by sepsis using the human protein Annexin A5.

As originally reported by CTV News, Scientists at The Lawson Health Research Institute in London are optimistic about the treatment using the protein, which has been used with patients who have sepsis.

The protein itself has strong ant-inflammatory properties, however in this trial, the researchers are using a manufactured form of the protein.

A large number of critically ill COVID-19 patients develop sepsis around one to two days before developing acute respiratory distress syndrome (ARDS) and organ failure.

The Lawson Health Research Institute has found success in a previous study using the protein in animals. The protein was used to block inflammation and improve organ function when treating sepsis.

If successful in humans, the protein would reduce hyperinflammation associated with sepsis and prevent respiratory and multi-organ failure.  It would also prevent blood clots or dying off cells caused by the illness.

The trial is in early stages and further testing will be conducted to determine it's success.  

More from Local News

Comments

Add a comment

Log in to the club or enter your details below.
Rating *

Weather